Effector Therapeutics Inc (EFTR) — Cash Flow Reinvestment Rate

Latest as of June 2020: 0.00x

Effector Therapeutics Inc (EFTR) has a Cash Flow Reinvestment Rate of 0.00x as of June 2020, reinvesting $0.00 (capex $0.00 ) from operating cash flow of $11.98 Million. Check Effector Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.00x
(Capex + Investments) / Operating CF

Total Reinvested

$0.00
Capex + Investments

Operating Cash Flow

$11.98 Million
USD

Capital Expenditures

$0.00
USD

Effector Therapeutics Inc Cash Flow Reinvestment Rate (2020–2020)

Historical reinvestment intensity for Effector Therapeutics Inc across 1 annual periods. Explore EFTR operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Effector Therapeutics Inc (2020–2020)

Year-by-year capital reinvestment analysis for Effector Therapeutics Inc. For live market cap and broader valuation context, see Effector Therapeutics Inc market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2020 0.02x $308.00K $13.84 Million $154.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow